Latest News
From the Journals
Mogamulizumab active in HTLV-1–associated myelopathy
The phase 1-2a study shows potential for mogamulizumab in the treatment of HAM-TSP.
Conference Coverage
On-label stent use looks safe in intracranial atherosclerotic disease
LOS ANGELES – The postmarketing WEAVE study suggests on-label use is key to an acceptable safety profile.
Conference Coverage
VIDEO: Advanced practice providers take on many roles in MS care
SAN DIEGO – Survey finds most MS advanced practice providers are highly satisfied with their jobs, patients, and colleagues.
Conference Coverage
‘Real-world evidence’ used to compare agents for relapsing-remitting MS
SAN DIEGO – The comparative effectiveness of delayed-release dimethyl fumarate was analyzed against fingolimod and glatiramer acetate.
Conference Coverage
Aspirin blunts early stroke risk from preeclampsia
Aspirin use dampened the rise in early-onset strokes seen after preeclampsia.
Conference Coverage
Imaging methods for stroke thrombectomy eligibility yield similar results
Stroke patients who were treated with thrombectomy at 6-24 hours fared equally well whether CT or MR imaging was used to assess their infarct.
Conference Coverage
Trial of clozapine, risperidone halted in MS
SAN DIEGO – Adverse events led to participants’ withdrawal.
Conference Coverage
VIDEO: Rivaroxaban plus aspirin halves ischemic strokes
In patients with stable atherosclerotic vascular disease, treatment with low-dose rivaroxaban plus aspirin halved the incidence of ischemic...
Conference Coverage
VIDEO: Retinal infarctions get missed as stroke harbingers
LOS ANGELES – Review of more than 5,000 Medicare beneficiaries with retinal infarction showed most don’t receive follow-up stroke assessment.
Conference Coverage
MedPAC mulls boost to payments for E&M visits
WASHINGTON – The commissioners debated whether the pay boost would make a difference.
Conference Coverage
VIDEO: Managing the alemtuzumab paradox
SAN DIEGO – Dr. Alasdair Coles explains the best management approach for this “high risk, high gain” drug.